Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

Quercetin reduced scalp soreness and may help with histamine-related hair loss. The soreness felt like inflamed follicles beneath the scalp surface.

Clascosterone (CB0301) is expensive due to concentrated form and lack of market competition. Users discuss sourcing from Indian and Chinese pharmacies for cheaper alternatives, but express concerns about product quality.

OP is trying to make a 1% cetirizine topical solution using minoxidil and needs to know how many cetirizine pills to crush. Users suggest using 60 pills, but results for similar treatments are unclear and take time.

The conversation is about using a DIY topical Cetirizine 1% solution with microneedling for hair loss treatment. Concerns were raised about potential side effects and the effectiveness of Cetirizine for this purpose.

The user is experiencing persistent scalp inflammation and itching, diagnosed as seborrheic dermatitis, but treatments like ketoconazole, finasteride, and RU58841 have been ineffective. Suggestions include using essential oils, turmeric with black pepper, lifestyle changes, and considering other conditions like autoimmune disorders.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

Clascoterone (Breezula) is anticipated for release in the coming years but is considered too weak for aggressive androgenetic alopecia (AGA). Current treatments like minoxidil, finasteride, and dutasteride are preferred, with some users obtaining clascoterone from the gray market.

Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.

The user is experiencing diffuse thinning and receded hairline, using dutasteride, minoxidil, and ketoconazole without regrowth, and was prescribed clobetasol propionate 0.05% with salicylic acid for possible inflammation. Other users caution against using the strong steroid without a serious condition, sharing experiences of adverse effects and alternative treatments for scalp issues.

The user is experiencing CCCA and is using finasteride and minoxidil, but still has a burning scalp and a persistent bald spot. They are considering dietary changes to reduce inflammation, questioning the impact of red meat, and seeking tips for scalp inflammation reduction.

Clascoterone is nearing regulatory submission as a potential new treatment for androgenetic alopecia, with positive Phase III results, while discussions continue about other treatments like PP405, minoxidil, and finasteride. Some users express excitement for clascoterone and Breezula, despite concerns about the effectiveness and practicality of topical treatments.

The user visited a trichologist due to ineffective topical finasteride treatment for hair loss. The trichologist recommended a new regimen including a two-month course of locoidon (cortisone 0.1%), followed by a solution containing minoxidil, hydrocortisone butirrate, estrone, progesterone, tocopherol acetate, trichosol, and transcutol.